title: Added-value of SPECT/CT to lymphatic mapping and sentinel lymphadenectomy in gynaecological cancers.
abstract: Lymphatic mapping and sentinel lymphadenectomy (LM/SL) have been successfully used in pre-treatment nodal staging of gynaecological cancers. We hypothesised the added-value of LM/SL plus SPECT/CT in patients with early stage of cervical cancer and vulvar cancer. A prospective, single-center, diagnostic, open label, active control, non-randomized clinical trial has been conducted in 7 patients with FIGO IA-IB1 cervical cancer and 7 patients with FIGO stage I-II-IIIcN0 vulvar cancer. All patients underwent LM/SL plus SPECT/low-dose CT and complete lymph node dissection (CLND) according to the standard of care. In case of negative hematoxylin-eosin staining, serial sections of the SLNs were analysed by immunohistochemistry and high molecular weight cytokeratin. Primary outcome measures were the detection rate, the sensitivity (SV), the negative predictive value (NPV), the diagnostic accuracy (DA) for anatomic localisation of SLNs, and the impact on management of SPECT/CT guided LM/SL versus CLND. The secondary outcome measure was the patient tolerability and operating time of LM/SL guided SPECT/CT versus CLND. http://clinicaltrials.gov/show/NCT00773071 All 14 patients were enrolled into the 1-day research protocol with dual-tracer LM/SL and SPECT/CT. Additional SLNs were detected on SPECT/CT compared to conventional planar imaging. Hot and cold > 1cm SLNs were detected on SPECT/CT. Detection rate, SV, NPV, DA were 100% in both groups; false negative rate was 0%. Rate of SLN metastases was 28.5% in cervical cancer and 42.9% in vulvar cancer. Impact on treatment was 28.5% and 14.3% in cervical cancer and vulvar cancer patients, respectively. SPECT/CT was well tolerated by all patients and operating time for LM/SL was within 30 min. No adverse events were reported with a time frame of 1-to-3 years. In early stage of gynaecological cancers, SPECT/low-dose CT is technically feasible and of clinical added-value for LM/SL.
authors.affiliation: Department of Medical Imaging-Nuclear Medicine, Western University London, ON, Canada.
authors.forename: Tarik Z
authors.initials: TZ
authors.lastname: Belhocine
authors.forename: Michel
authors.initials: M
authors.lastname: Prefontaine
authors.forename: Dominique
authors.initials: D
authors.lastname: Lanvin
authors.forename: Monique
authors.initials: M
authors.lastname: Bertrand
authors.forename: Irina
authors.initials: I
authors.lastname: Rachinsky
authors.forename: Helen
authors.initials: H
authors.lastname: Ettler
authors.forename: Pamela
authors.initials: P
authors.lastname: Zabel
authors.forename: Larry W
authors.initials: LW
authors.lastname: Stitt
authors.forename: Akira
authors.initials: A
authors.lastname: Sugimoto
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Urbain
keywords: LM/SL; SPECT/CT; cervical cancer; vulvar cancer